0001562180-18-004886.txt : 20181207 0001562180-18-004886.hdr.sgml : 20181207 20181207160744 ACCESSION NUMBER: 0001562180-18-004886 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181206 FILED AS OF DATE: 20181207 DATE AS OF CHANGE: 20181207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moses Jennifer K. CENTRAL INDEX KEY: 0001706667 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 181223552 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-12-06 false 0001560241 G1 Therapeutics, Inc. GTHX 0001706667 Moses Jennifer K. C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR. 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 false true false false VP of Finance & Admin Common Stock 2018-12-06 4 M false 750.00 0.39 A 2750.00 D Common Stock 2018-12-06 4 S false 750.00 34.00 D 2000.00 D Common Stock 2018-12-07 4 M false 2000.00 3.72 A 4000.00 D Stock Options (Right to Buy) 0.39 2018-12-06 4 M false 750.00 0.00 D 2024-07-11 Common Stock 750.00 1666.00 D Stock Option (Right to Buy) 3.72 2018-12-07 4 M false 2000.00 0.00 D 2025-12-21 Common Stock 2000.00 10333.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. All shares underlying this option have vested. The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. /s/ James Stillman Hanson, attorney-in-fact 2018-12-07